# OnCo record nct05431270 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05431270/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05431270", "NCT05431270" ;
  schema:name "Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy"@en ;
  schema:alternateName "MORNINGSTAR"@en ;
  schema:description "A phase 1/2 trial of Mavrostobart, Tislelizumab, Gemcitabine in non-small-cell lung cancer and small-cell lung cancer, run by Phanes Therapeutics, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05431270/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05431270> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2022-08-11" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:drugs <https://onco.cc/drugs/mavrostobart/>, <https://onco.cc/drugs/tislelizumab/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/pemetrexed/> ;
  onco:companies <https://onco.cc/companies/phanes-therapeutics/> .